Floatz logo

IMIPENEM

Pneumonia, Bacterial

Hartford HospitalSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pneumonia, Bacterial cohort.

Asset / SponsorPhaseRating
Cefiderocol
Hartford Hospital
Phase 4BB
CILASTATIN
Hartford Hospital
Phase 4B
RELEBACTAM
Hartford Hospital
Phase 4CCC

Same molecule, other indications

IMIPENEM is also rated in:

Critical IllnessDormant
BB
Indicative ·
65 / 100
View asset →
cystic fibrosisDormant
B
Indicative ·
59 / 100
View asset →
cirrhosis of liverDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →